Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017 (2017), Article ID 9820181, 11 pages
https://doi.org/10.1155/2017/9820181
Review Article

Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex

1Centre for Child Development, Neuropediatrics Unit, Pediatric Hospital, Coimbra Hospital and University Centre, Coimbra, Portugal
2Laboratory of Pharmacology & Experimental Therapeutics, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Coimbra, Portugal
3Centre for Neuroscience and Cell Biology-Institute for Biomedical Imaging and Life Sciences (CNC.IBILI) Research Consortium, University of Coimbra, Coimbra, Portugal

Correspondence should be addressed to Filipe Palavra; moc.liamg@arvalapepilif

Received 2 December 2016; Revised 11 February 2017; Accepted 21 February 2017; Published 12 March 2017

Academic Editor: Giuseppe Filomeni

Copyright © 2017 Filipe Palavra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Filipe Palavra, Conceição Robalo, and Flávio Reis, “Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 9820181, 11 pages, 2017. doi:10.1155/2017/9820181